Drugs / DZD6008
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06905197 | May 2025 → Sep 2027 expected | non-small cell lung carcinoma | Dizal Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06813365 | Jun 2024 → Dec 2026 expected | non-small cell lung carcinoma | Dizal Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07079475 | Jul 2025 → Jun 2028 expected | non-small cell lung carcinoma | Dizal Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07070440 | Jul 2025 → Jun 2027 expected | non-small cell lung carcinoma | Dizal Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DZD6008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07070440 ↗ |
| Action | Inhibit | “Oral EGFR Inhibitor” NCT06813365 ↗ |
| Route | Oral | “Oral EGFR Inhibitor” NCT06813365 ↗ |
| Target | EGFR | “Oral EGFR Inhibitor” NCT06813365 ↗ |